NASDAQ:MIRA

MIRA Pharmaceuticals Q3 2026 Earnings Results & Report

MIRA Pharmaceuticals logo
$0.59 -0.05 (-7.66%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$0.60 +0.01 (+1.18%)
As of 11/18/2026 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MIRA Pharmaceuticals met analyst earnings expectations in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$0.03 versus the -$0.03 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes

MIRA Pharmaceuticals EPS Results

Actual EPS
-$0.03
Consensus EPS
-$0.03
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

MIRA Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

MIRA Pharmaceuticals' next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules.

Conference Call Resources

MIRA Pharmaceuticals Q3 2026 Earnings FAQ

MIRA Pharmaceuticals (NASDAQ:MIRA) reported earnings of -$0.03 per share for Q3 2026, matching the consensus estimate of -$0.03. The report was announced on Monday, November 16, 2026.

MIRA Pharmaceuticals' next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for MIRA Pharmaceuticals on the company's earnings history page.

MIRA Pharmaceuticals Earnings Headlines

Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
MIRA Pharmaceuticals (NASDAQ:MIRA) Shares Up 0.3% - Time to Buy?
See More MIRA Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MIRA Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MIRA Pharmaceuticals and other key companies, straight to your email.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage pharmaceutical company developing oral drug candidates for neurological and neuropsychiatric conditions. Its pipeline includes MIRA1a, an investigational synthetic cannabinoid analog being studied for potential use in conditions such as anxiety and chronic pain.

The company has also added Ketamir-2, an investigational oral ketamine analog being developed for potential treatment of depression and neuropathic pain. These candidates remain in development and are not approved medicines.

View MIRA Pharmaceuticals Profile